FDA’s Crawford gets strong four-month review
Acting FDA Commissioner Lester Crawford "is doing an awesome job," HHS Secretary Tommy Thompson tells medical device association AdvaMed June 20. "He is out there to make changes. He is already making more changes in the short couple [of] months he's been here...realigning, reorganizing, putting in the risk assessment system....Whether or not he's going to get to be the commissioner, I can't tell you. That's a decision for the President. But I can assure you, until the final commissioner is appointed by the President, this man is in charge"...
You may also be interested in...
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.
Enjoying a 5% sales rise, Bayer Consumer Health grew faster than the global market last year, with the company keen to repeat the performance in 2021.